Back to Search Start Over

Unilateral or Bilateral Retroperitoneal Lymph Node Dissection in Nonseminoma Patients with Postchemotherapy Residual Tumour? Results from RETROP, a Population-based Mapping Study by the Swedish Norwegian Testicular Cancer Group.

Authors :
Gerdtsson A
Thor A
Grenabo Bergdahl A
Almås B
Håkansson U
Törnblom M
Negaard HFS
Glimelius I
Halvorsen D
Karlsdóttir Á
Sagstuen Haugnes H
Engen Andreassen K
Melsen Larsen S
Holmberg G
Wahlqvist R
Tandstad T
Cohn-Cedermark G
Ståhl O
Kjellman A
Source :
European urology oncology [Eur Urol Oncol] 2022 Apr; Vol. 5 (2), pp. 235-243. Date of Electronic Publication: 2021 Mar 06.
Publication Year :
2022

Abstract

Background: The distribution of retroperitoneal lymph node metastases for patients with nonseminoma and a residual tumour of 10-49 mm in a population-based setting is unknown. This information is needed to justify selection of patients for a unilateral template resection.<br />Objective: To describe the location of retroperitoneal metastases and recurrences in patients with nonseminoma germ cell tumour (NSGCT) with a residual tumour of 10-49 mm.<br />Design, Setting, and Participants: RETROP is a population-based prospective observational mapping study of 213 patients in Sweden and Norway with a retroperitoneal residual tumour of 10-49 mm who underwent postchemotherapy retroperitoneal lymph node dissection for metastatic NSGCT during 2007-2014 with median follow-up of 100 mo. Patients were classified according to the testis primary tumour and the distribution of unilateral or bilateral lymph node metastases (with reference to the aorta) present on pre- and/or postchemotherapy computed tomography (CT) scans.<br />Outcome Measurements and Statistical Analysis: The distribution and rate of teratoma or cancer in unilateral or bilateral retroperitoneal fields and the location and rate of retroperitoneal recurrence were measured.<br />Results and Limitations: In total, 65% of the patients had unilateral retroperitoneal lymph node metastases (RLNMs) on CT scans. Patients with unilateral RLNMs had a low risk of contralateral teratoma or cancer (1.6% for right- and 2.6% for left-sided NSGCT) or retroperitoneal recurrence (0% for right- and 4% for left-sided NSGCT). A weakness of the study is that the pathology specimen could not be fully designated to one specific area for some of the patients.<br />Conclusions: Men with postchemotherapy residual disease of 10-49 mm and unilateral metastases on pre- and postchemotherapy CT scans have a low risk of contralateral disease and should be considered for a unilateral template resection.<br />Patient Summary: The surgeon can use computed tomography (CT) scans in deciding on the extent of lymph node dissection in patients with testicular cancer.<br /> (Copyright © 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.)

Details

Language :
English
ISSN :
2588-9311
Volume :
5
Issue :
2
Database :
MEDLINE
Journal :
European urology oncology
Publication Type :
Academic Journal
Accession number :
33750683
Full Text :
https://doi.org/10.1016/j.euo.2021.02.002